Standard BioTools Receives $30M Illumina Earnout And Royalty Buyout; Agrees To Sell Mass Cytometry Business For Up To $10M Ahead Of Treeline Merger
Share
Why It Matters
Standard BioTools is getting $30 million from Illumina and selling off one of its business parts for up to $10 million to get ready for merging with another company called Treeline. This shows the company is cleaning up its pieces before a big change.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.